Nelly ZIADE 🍀 Nellziade
2 months ago
WIN Nutrition session at #EULAR2026 (2)
🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals.
🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies.
@RheumNow
Nelly ZIADE 🍀 Nellziade
2 months ago
WIN Nutrition session at #EULAR2026 (1)
🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset
🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35)
@rheumnow https://t.co/RhO08FXtLI
sheila RHEUMarampa
2 months ago
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesn’t really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
Bella Mehta bella_mehta
2 months ago
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Mrinalini Dey DrMiniDey
2 months ago
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
Jiha Lee JihaRheum
2 months ago
Catching your breath session at #EULAR2026
RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr)
Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks)
@RheumNow https://t.co/V1JXM3i9wP
Dr. John Cush RheumNow
2 months ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment
sheila RHEUMarampa
2 months ago
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Bella Mehta bella_mehta
2 months ago
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow
Summary below. https://t.co/QC0Li38eh6
Aurelie Najm AurelieRheumo
2 months ago
SCOOT study oral split-dose vs SC MTX RA
Primary outcome EULAR mod/good response wk16
Non-inferiority NOT met
EULAR good response lower with oral split-dose OR 0.53
ACR50 lower with oral split-dose OR 0.51
Safety oral split-dose Higher transaminitis (>2× ULN)
3 serious AEs https://t.co/c8etFKtGwo
Jiha Lee JihaRheum
2 months ago
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Mrinalini Dey DrMiniDey
2 months ago
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Mrinalini Dey DrMiniDey
2 months ago
#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow
https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
